Study of sul-238 for early untreated parkinson's disease
Part of Brain & nervous system clinical trials.
This study tests whether an experimental medicine called SUL-238 can improve energy levels in the brain cells of people with early, untreated Parkinson's. It uses a special type of MRI to see if the medicine affects brain energy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with Parkinson's disease within the last year.
- You have not yet taken any Parkinson's disease medication.
- Your Parkinson's symptoms are mild — you can walk independently, and balance is mostly fine.
- You are 40 years or older.
- You can have an MRI scan (no metal implants, pacemaker, etc.).
- You are not taking high-dose vitamin E or other supplements that affect mitochondria.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational imaging agent called SST001, which may help doctors see a protein linked to Parkinson's disease (PD) and multiple system atrophy (MSA) in the body. It will be given to healthy volunteers and patients with PD or MSA to check safety, how it spreads, and how the body handles it.
This study tests whether an experimental oral medication (TJ0113) can improve symptoms in people diagnosed with Parkinson's disease before age 50. Participants must already be taking levodopa and keep their current Parkinson's medications unchanged during the study.
This study tests an experimental medicine called ENERGI-F705 to see if it can help people with Parkinson's disease. It focuses on people who have had the disease for at least 2 years and are currently on standard Parkinson's medications, without major movement complications.
This trial tests a new oral medicine, GT-02287, to see if it can help people with early Parkinson's disease. It aims to improve symptoms and slow the disease, and it also tracks how the medicine affects certain markers in the body.
This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.
This trial tests whether the anti-inflammatory drug dapansutrile can help people with early Parkinson's disease. You would get either dapansutrile or a placebo (a pill with no active drug) to see if it slows the disease.
Hear when a new Parkinson's Disease (PD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.